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tumors in the lung in octogenarians: a
retrospective single institution study
Nathan A Cannon, Puneeth Iyengar, Hak Choy, Robert Timmerman and Jeffrey Meyer*Abstract
Background: Treatment of cancer in the lung in octogenarians is limited by their health and functional status.
Stereotactic ablative radiotherapy is an established noninvasive treatment option for medically inoperable patients,
with a toxicity profile that may be more tolerable in elderly patients.
Methods: Patients more than 80 years old treated with stereotactic ablative radiotherapy for malignant tumors in
the lung between January 2007 and August 2012 at a single institution were identified and retrospectively analyzed
for toxicity and survival.
Results: Thirty patients were identified with a total of 32 lesions treated. Patients ranged in age from 80.8 to
90.7 years old (median 84.9) at the time of treatment. Twenty patients had ECOG performance status 0–1, and 10
had performance status 2–3. Stage distribution at treatment was: stage I (20 patients), stage III (1), stage IV (1), and
8 recurrent tumors. Patients were treated to a median total dose of 54 Gy in 3 fractions (range 20–60 Gy in 1 to
5 fractions). Median follow up was 13 months (range 2–60 months). Fifteen patients were still living at last review.
There was one failure in field and one failure in the same lobe that was treated. One patient died with progressive
regional disease, and four died of progressive metastatic disease. Three patients had late grade 3 pulmonary
dyspnea with no grade 4 or 5 toxicities. One patient had late grade 2 pneumonitis, and 3 patients had late grade 1
pneumonitis. Three patients had grade 1 chest wall pain.
Conclusions: Octogenarians tolerated ablative treatment with minimal toxicity. Stereotactic ablative body radiotherapy
is an option to consider in treatment of elderly patients.
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The ability to treat elderly patients with cancer is compli-
cated due to the increasing comorbidities and decreasing
functional status associated with aging [1]. Whether or
not age is an independent predictor of poor treatment tol-
erance remains an area of controversy. For elderly patients
treated for lung cancer, declining health means that they
may not be candidates for radical surgery and must turn
to other options including radiation therapy for manage-
ment of their localized disease.
For those patients that are not candidates for surgery,
conventionally fractionated radiation therapy (e.g., 2 Gy* Correspondence: Jeffrey.Meyer@utsouthwestern.edu
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unless otherwise stated.per treatment for 30 treatments) has been associated
with poor survival [2,3]. While the efficacy of radiation
treatments does not inherently decline with age [4], tar-
geted tumor control with conventional radiation therapy
is significantly inferior to that achieved with lobectomy or
sublobar resection [5]. Thus, there is significant interest in
alternate treatment options in this group of patients. A
variety of thermal ablation techniques are currently used
to treat patients with primary and secondary lung cancers
occurring in medically inoperable patients [6]. Stereotactic
ablative radiotherapy (SABR), also known as stereotactic
body radiation therapy (SBRT), is another treatment mo-
dality that utilizes advanced planning and image-guidance
technologies to deliver potent doses of radiation to discrete
tumors in a short treatment course. The dose potenciesl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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CCI is Charlson commorbidity index.
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itional, conventionally fractionated radiation therapy (e.g.,
2 Gy per day given 30 times). A phase II study established
SABR as an effective non-surgical therapy for selected pa-
tients with medically inoperable early-stage lung cancer,
with local control and survival results considerably super-
ior to those historically seen with conventional radiation.
In this study, the median age of patients was 72 years [7].
Since SABR is a relatively new treatment modality, there
are few studies examining its tolerability and oncologic
outcomes in significantly older patients.
We retrospectively examined the experience of patients
more than 80 years old treated for tumors in the lung with
SABR at a single institution to determine how well these
patients tolerated treatment in terms of toxicity following
treatment. We also examined the disease free and overall
survival of these patients.
Methods
Between 1/1/2007 and 8/31/2012, 33 patients were
treated with SABR to the lung at the University of Texas
Southwestern Medical Center who were over the age of
80 (age range 80 to 90 years old) at the time of their first
SABR treatment. All patients were either not candidates
for lobectomy or declined surgery. Three patients had no
follow-up at our institution after treatment and were
excluded from the analyses. Comorbidities and demogra-
phics are listed in Table 1. Comborbidity definitions are
based on previous diagnoses, treatments, or events. Pul-
monary comorbidities include emphysema, COPD, and
asthma. Cardiac disease included CHF, atrial fibrillation,
and a history of myocardial infarction. Hepatic disease in-
cludes viral hepatitis and cirrhosis. Patients were evaluated
retrospectively as part of an Institutional Review Board
approved research review. Patients were staged based on
AJCC version 7 based on the stage of disease at the time
of presentation for SABR. Patients with recurrent disease
were considered to have stage IV disease except for 2
patients with bronchoalveolar carcinoma who had previ-
ously resected lesions who were classified as stage I. Tumor
location, size, and outcomes are reported in Table 2.
For SABR treatments, patients were immobilized within
a large vacuum pillow inside either a commercially available
Elekta Stereotactic Body Frame® (Elekta, Crawley, United
Kingdom) or a larger carbon fiber body frame. Abdominal
compression was applied if tumor motion was greater than
1.0 cm in any direction based on fluoroscopy prior to
obtaining CT simulation. Maximum intensity projection
(MIP) images from a 4-dimensional CT were registered
with the simulation CT scan. The internal target volume
(ITV) was defined using MIP images or a Boolean union
of inspiration and expiration phases. The planning target
volume (PTV) was generated through a 0.5 cm expan-
sion of the ITV in all directions. A treatment plan wasgenerated using 7–13 non-coplanar, non-opposing beams
using Pinnacle planning software (Phillips, Amsterdam,
Netherlands). Treatment was delivered in 1 to 8 frac-
tions over 1 to 22 days. Prescribed doses ranged from
20 to 60 Gy. (Table 3) Doses were prescribed to the
isodose shell covering the PTV (median: 77%, range: 69-
97%). One patient was treated to 60 Gy in 3 fractions pre-
heterogeneity correction, which is similar to the 54 Gy in
3 fractions with heterogeneity correction. Total dose and
fractionation were determined based on the site of the dis-
ease (central versus peripheral), stage, trial participation,
as well as nearby organ at risk tolerability as determined
by the treating physician. Patients were generally treated
every other day.
Follow-up generally consisted of physical examination
and CT scan every 3 months for the first year followed
by continued exams with CT scans every 6 months. If
there were suspicious findings including increase in size
of post-radiation scarring or the development of a new
nodule or enlarged lymph node, a PET-CT was performed,
and FDG-avidity was considered evidence of recurrent
disease. If there was still doubt, a biopsy was performed.
The Common Terminology Criteria for Adverse Events
version 4.0 was used to evaluate toxicity. Dyspnea was
defined as shortness of breath with exertion which was
persistent. Pneumonitis was defined as shortness of breath
Table 2 Summary of patient presentation and outcome
Patient Location Size Central Stage Survival Status
1 LUL 2.9 IA Alive Hillar failure, to hospice
2 LUL 1.5 IA Alive No evidence of disease
3 LUL 2.8 Yes IA Alive No evidence of disease
4 RUL 3.5 IA Alive No evidence of disease
5 LLL 2.3 IA Alive No evidence of disease
6 LUL 2.2 IA Alive No evidence of disease
7 LUL 2.3 IA Deceased Hillar and contralateral failure, hospice
8 LUL 2.4 Yes IA Deceased No evidence of disease
9 LUL 1 IA Deceased No evidence of disease
10 LUL 5.5 Yes IB Alive No evidence of disease
11 RUL 4 IB Alive No evidence of disease
12 RUL 4.7 Yes IB Alive No evidence of disease
13 LUL 3 IB Alive No evidence of disease
14 LLL 3.6 IB Alive No evidence of disease
15 RML 4.5 Yes IB Alive No evidence of disease
16 RLL 4.3 IB Deceased Brain metastases, whole brain radiation
17 RML 3.9 IB Deceased No evidence of disease
18 RLL 3.4 IB Deceased No evidence of disease
19 LUL 3.9 Yes IB Deceased No evidence of disease
20 RLL 3.1 IB Deceased No evidence of disease
21 LUL, LUL 1.8, 1.4 IA Alive No evidence of disease
22 RUL 3.2 IA Alive Failure in the same lobe, SABR
23 RUL 2 Yes III Alive No evidence of disease
24 LUL 2 IA Deceased Malignant pleural effusion, hospice
25 LUL 2.2 IA Deceased Failure at primary and supraclavicular, SABR and tarceva
26 RLL 6.6 IB Deceased No evidence of disease
27 RLL 3 IV Deceased No evidence of disease
28 RLL 2.3 III Deceased Failure in abdominal soft tissue, tarceva
29 LLL 2.3 IV Deceased No evidence of disease
30 RUL, RML 4, 1.5 IV Deceased Distant failure in bone, SABR to bone
Therapy at recurrence is noted.
Cannon et al. BMC Cancer 2014, 14:971 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/971with associated symptoms such as fever or cough which
resolved after treatment with steroids.
Overall survival was calculated using the Kaplan-Meier
methods. Comparisons between groups were made using
the log-rank method. Results were considered significant
with a P value <0.05. P values were derived from univariate
analysis. SPSS version 21 was used for all statistical ana-
lyses. (SPSS Inc., Chicago, Illinois, USA) Survival was mea-
sured from the first treatment with SABR.
This study was approved by the University of Texas
Southwestern Institutional Review Board.
Results
Between 1/1/2007 and 8/31/2012, 33 patients who were
over the age of 80 at the time of first treatment underwentSABR. Three patients had no follow-up after their last
treatment and were excluded from further review, leaving
30 patients in the final analyses with median age of
84.9 years at the time of first treatment. Of the 30 patients
eligible for the study, 28 are known to have had a biopsy
proven nonsmall cell lung carcinoma. One patient had
metastatic renal cell carcinoma to the lung treated with
SABR. One patient had a biopsy at an outside hospital,
and the reports were not available for review but were
noted to be nonsmall cell lung carcinoma in the patient’s
chart. A total of 32 lesions were treated. Two patients
were treated to two isocenters: one with metastatic renal
cell and the other with bronchoalveolar carcinoma.
Twenty patients had stage I non-small cell lung cancer
(9 stage IA and 11 stage IB). Nine patients were treated
Table 3 Dose fractionation summary
Total dose Fractions Dose per fraction (Gy) Number of patients
20 3 6.67 1
30 5 6 1
34 1 34 1
35 5 7 1
40 5 8 1
48 8 6 1
50 5 10 5
53 5 10.5 1
54 3 18 13
55 5 11 1
60 3 20 1
60 5 12 7
Figure 1 Overall survival of octogenarians treated with SABR.
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Two of these patients had bronchoalveolar carcinoma
and were treated to new sites of disease (patients 21 and
24, see Table 2). Patient 22 had stage IB carcinoma of
the lung but was not a surgical candidate. This patient
was initially treated with chemoradiotherapy but had
progression at the primary site, which was subsequently
treated with SABR. Patient 23 had stage III (T2N2M0)
non-small cell lung cancer treated with surgical resec-
tion. This patient was treated with carboplatin and pacli-
taxal with bevacizumab at the time of first progression
in the mediastinum. The patient recurred a second time
following chemotherapy, this time in the contralateral
lung. The site of second recurrence was treated with
SABR. Two patients (patient 25 and 26) had a previous
resection and were treated with SABR at the time of
recurrence in an isolated nodule. Patient 27 had stage IV
disease previously treated with carboplatin and paclitaxal
followed by navelbine and later topotecan. This patient
was treated to a single progressive lesion in the lung.
Also, 2 patients were treated to isolated nodules in con-
junction with concurrent chemoradiation to the primary
and mediastinum (patients 28 and 29). Patient 30 had
metastatic renal cell carcinoma and was treated to 2 sites
of metastatic disease.
Nine patients had a previous diagnosis of non-lung
cancer. Of these patients, 7 had been previously treated
and had control of the cancer. One had recently been
diagnosed with prostate cancer and declined treatment;
the lung cancer was discovered on staging workup. The
final patient had metastatic renal cell carcinoma to the
lung and abdominal lymph nodes, all of which were
treated with SABR.
Nineteen patients had ECOG performance status 0–1
at time of treatment, and 11 had performance status 2–3.
The distribution of the stage of the patients is shown in
Table 2. Seven of the tumors were in a central location(within 2 cm of the proximal bronchial tree), and each of
these were treated with at least a 5 fraction regimen (total
dose 40–60 Gy).
Median follow up was 13 months with a range from 2 to
61 months. There were no hospitalizations within 30 days
of completing treatment. Actuarial survival at one year
was 69%. (Figure 1) Fifteen patients remained alive at the
time of last follow-up. When patients were split into stage
I versus recurrent or advanced stage, the median survival
of patients with stage I disease was 17.7 months (95% con-
fidence interval 16.1-18.5 months), and the 2 year Kaplan-
Meier survival was 36%. The median survival of patients
with stage III-IV disease was 11.6 months (95% confidence
interval 7 to 17 months). (Figure 2) The difference in over-
all survival between early and recurrent or advanced stage
patients was not statistically significant. In patients with
early stage lung cancer treated with 3 or 5 fractions of
radiation, there was no difference in overall survival based
on the fractionation scheme (Figure 3).
Three patients failed in the ipsilateral lung. Patient 24
treated for bronchoalveolar carcinoma developed a malig-
nant pleural effusion and went to hospice 14 months after
treatment. The second patient (patient 22) was treated for
recurrent disease and developed a second tumor outside
of the radiation field in the same lobe that was treated.
This recurrence was treated with SABR one year after the
initial treatment which was complicated by pneumonitis.
The third patient (patient 25) had previously been treated
with surgical resection followed by SABR at the time of
recurrence. He developed progression of the primary
lesion. This patient died 26 months after the initial treat-
ment. Another patient had progression in the lungs, but
this was a site previously treated with conventional radi-
ation contralateral to the SABR treatment. Four of the pa-
tients who died had known metastatic disease at the time
of death and died without evidence of local progression.
Figure 2 Overall survival of patients with early and late stage
lung cancer. Stage 1 in solid line. Recurrent or advanced stage
disease in dashed line.
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time of initial treatment. Two patients died of other causes
(pneumonia and cardiac arrest). There were no treatment
related deaths. The cause of death was unknown in 7
patients.
Patients developed toxicity related to respiratory difficul-
ties and chest wall pain. The most common late side effect
was dyspnea. Three patients developed grade 1 dyspnea.
Three patients developed grade 3 dyspnea 1–12 months
after completing treatment. One patient developed grade 2
pneumonitis four months after finishing treatment which
resolved with a short course of steroids. Three patients de-
veloped grade 1 chest wall pain 1 to 9 months after treat-
ment. Two of these patients received 60 Gy in 5 fractions
and one received 54 Gy in 3 fractions. In total, 7 patients
experienced late toxicity associated with SABR. In patientsFigure 3 Survival of early stage patients in 3 and 5 fractions of
SABR. 3 fractions in solid line. 5 fractions in dashed ling.receiving 54 Gy in 3 fractions (14 patients including the
patient treated with 60 Gy in 3 fraction pre-heterogeneity
correction), 2 patients developed grade 3 dyspnea com-
pared to 1 patient with grade 2 and 1 patient with grade 3
dyspnea who were treated to 50 to 60 Gy in 5 fractions
(13 patients).
Discussion
The tolerance of the most elderly patients to intensive
cancer therapies, irrespective of comorbid conditions, is
an area of controversy. Laboratory studies have not defi-
nitively shown a relationship between age and increased
sensitivity to radiation for skin, vascular smooth muscle
cells, and chromosomal breaks [8-10]. Clinical reports
have shown conflicting data, but the available evidence
suggests that older patients with lung cancer undergoing
concurrent chemotherapy and radiation therapy have
higher rates of pneumonitis and hematologic toxicity com-
pared to younger patients [11].
SABR is now an established option for the manage-
ment of early-stage lung cancer in patients who are not
candidates for conventional surgery because of medical
comorbidities. Although many of these patients are eld-
erly, the safety and efficacy of high-dose focal irradiation
in octogenarian and older patients is not well defined.
One of the hallmarks of SABR is delivery of radiation
doses (typically in the range of 8–20 Gy per fraction)
that are significantly higher than those delivered with
more conventional fractionated irradiation. Advances in
treatment planning and delivery have allowed the highest
doses to be conformally confined to the tumor volume,
but there is nonetheless a zone of intermediate falloff dose
within normal tissue that may be poorly tolerated in eld-
erly tissues.
Many studies have looked at the feasibility of surgical
treatments in octogenarians who are fit for surgery. Trad-
itional open surgeries can be tolerated in carefully selected
octogenarians [12,13]. More recently, video assisted thora-
coscopic surgery (VATS) has been found to be tolerable
with similar rates of perioperative mortality and survival
to open surgery in octogenarians [14-18]. VATS has also
been shown to have fewer complications following open
surgeries [19]. Surgery has remained the primary modality
of treatment in the elderly and octogenarians for patients
with early stage lung cancer due to its superior overall
survival compared to conventional radiation or chemo-
therapy [5]. Unfortunately, many elderly patients with lung
cancer have multiple comorbidities which make them poor
candidates for surgery, with 88% having at least 1 and 54%
having 3 or more comorbidities [1].
Despite the lack of evidence for its benefits in this
population, SABR is becoming more common in the eld-
erly and in octogenarians [20]. Preliminary data indicate
that age is not a significant predictor of overall survival
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performance status is a predictor of poor outcome [21,22].
Recent studies of SABR in octogenarians with early stage
lung cancer showed that patients tolerated a 5 fraction regi-
men well with minimal side effects (Table 4) [21,23-26].
Takeda et al. showed a 3 year overall survival and lung
cancer specific survival of 53.7 and 70.8% respectively.
The majority of patients in our study were treated with a
3 fraction regimen which is common in the United States.
The patients with early stage disease in our study had
2 year actuarial survival of 41%. In our study, there was no
difference in survival between patients receiving treatment
in 3 or 5 fractions.
With toxicity being a major concern in elderly patients,
limiting the side effects of treatment is critical. Samuel
et al. examined toxicity in elderly patients treated with
SABR with 3 or 4 fractions [24]. They did not observe any
grade 3 toxicity. All of the studies examining SABR in
elderly patients have shown relatively low rates of grade 3
toxicity ranging from 0-10%, but they did not compare
toxicity rates in patients based on fractionation schedule.
Overall, these rates of toxicity are similar to those seen for
younger patients treated with SABR [7]. In our study,
there was no difference in the rates of dyspnea or pneu-
monitis when comparing treatments of 3 or 5 fractions.
This is the first study to include both treatments of 3 and
5 fractions and compare them directly for toxicity. How-
ever, there is not sufficient power in our study to detect
small differences in side effects. These issues could be
examined in future studies.
Mounting evidence indicates that age alone should not
be a significant deciding factor in whether or not therapies
with curative intent are offered to patients with lung
cancer. In patients with locally advanced lung cancer,
Domingues et al. showed that definitive therapy with
radiation or concurrent chemotherapy and radiation in
elderly patients with a median age of 71 (range 65–90)
significantly increased the overall survival of patients
compared to palliative care alone, and this survival advan-
tage remained for those patients over the age of 75 [27].








Hasbeek 79(75) 193 7 60 3-8
Sugane 82(80) 28 0 52.8-72 4-9
Samuel 82(75) 46 0 48-60 3-5
Takeda 83(80) 109 6 40-50 5
Van der
Voort
82(80) 38 5 48-60 3-6
Present 85(80) 30 10 20-60 1-8of 80 and concluded that patients would benefit from
definitive therapy with radiation or chemotherapy [28].
Our study showed that patients with recurrent or advan-
ced cancer tolerated treatment well with minimal side ef-
fects and obtained good local control based on 7 patients
with stage III or IV disease. While 12 month survival was
44%, and the median survival was 11.6 months. Control of
disease at the site of the lung mass could be beneficial in
these patients in terms of decreased symptoms of lung
collapse or obstructive pneumonia. This is the only study
which included patients with advanced stage disease who
were treated with SABR. While this included only 10 pa-
tients, the treatment was well tolerated, and there was one
in-field failure. None of the patients died of treatment
related toxicity or local progression, indicating that the
treatments were well tolerated and effective in preventing
complications of progressive disease at the site of treat-
ment. Further investigation of the benefits of these treat-
ments is warranted.
Conclusion
This study shows that SABR, including 3-fraction and
5-fraction treatments, is a viable treatment option in
octogenarians with cancer in the lung who are not
candidates for surgical resection. Further research should
be conducted to ascertain the full benefits of treatment in
these patients in terms of palliative benefit and improve-
ments in survival. The local control of the targeted disease
is very good with one in field failure in this study. Treating
patients with 3 or 5 fractions are both viable options
resulting in acceptable toxicity while affording impressive
rates of overall survival.
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